Advertisement

Der Urologe

, Volume 57, Issue 5, pp 532–542 | Cite as

Chemotherapieinduzierte Nausea und Emesis

Aktuelle Empfehlungen zur Prophylaxe
  • E. Storz
  • J. E. Gschwend
  • M. Retz
Leitthema
First Online:
  • 346 Downloads

Zusammenfassung

Die chemotherapieinduzierte Nausea und Emesis (CINE) gehören zu den häufigsten Nebenwirkungen der Zytostatikatherapie und stellen bei der Behandlung onkologischer Patienten eine große Herausforderung dar. Eine korrekte, leitliniengerechte antiemetische Prophylaxe ist daher unerlässlich und trägt wesentlich zum Behandlungserfolg bei. Diese Übersichtsarbeit fasst die aktuellen Empfehlungen der „Multinational Association of Supportive Care in Cancer“ (MASCC) und „European Society of Medical Oncology“ (ESMO), der „American Society for Clinical Oncology“ (ASCO), des „National Comprehensive Cancer Network“ (NCCN) sowie der S3-Leitlinie „Supportive Therapie“ vom „Leitlinienprogramm Onkologie“ zur Prophylaxe der CINE verständlich zusammen und soll deren Anwendung in der täglichen Routine erleichtern.

Schlüsselwörter

Antiemetische Therapie Zytostatikatherapie Leitlinien Emetogenität Glukokortikoide 

Abkürzungen

5-HT

5-Hydroxytryptamin (Serotonin)

5-HT3-Rezeptoren

5‑Hydroxytryptamin-3-Rezeptoren

ANS

Antineoplastische Substanz

ASCO

American Society for Clinical Oncology

AUC

„Area under the curve“

AUO

Arbeitsgemeinschaft Urologische Onkologie

BfArM

Bundesinstitut für Arzneimittel und Medizinprodukte

BID

bis in die (lat.: zweimal täglich)

CINE

Chemotherapiebedingte Nausea und Emesis

CYP

Cytochrom P

ESMO

European Society of Medical Oncology

i. v.

intravenös

INR

International Normalized Ratio

MASCC

Multinational Association of Supportive Care in Cancer

MCP

Metoclopramid

NCCN

National Comprehensive Cancer Network

NK1-Rezeptor

Neurokinin-Rezeptor 1

ZNS

Zentrales Nervensystem

Chemotherapy-induced nausea and vomiting

Current recommendations for prophylaxis

Abstract

The chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent side effects in cytostatic therapy and a profound challenge during the therapy of cancer patients. Therefore, standardized guideline-orientated prophylaxis is essential and a fundamental contribution for the success of treatment. This review summarizes the current recommendations for CINV of the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the S3-guideline Supportive Therapie of the Leitlinienprogramm Onkologie and shall facilitate its use in the daily routine.

Keywords

Antiemetics Cytostatics Guidelines Emetogenicity Glucocorticoids 
This is a preview of subscription content, log in to check access.

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

E. Storz, J. E. Gschwend und M. Retz geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    AOP (2016) Fachinformation zu CANEMES 1 mg Kaps. http://sr001017043/detailinfo.php?ID=3348522200. Zugegriffen: 02.01.18Google Scholar
  2. 2.
    Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2017) Leitlinienprogramm Onkologie: S3-Leitlinie Supportive Therapie bei onkologischen PateintInnen, Langversion 1.1, April 2017, AWMF Registrierungsnummer 032/054OL. http://leitlinienprogramm-onkologie.de/. Zugegriffen: 9. Dez. 2017Google Scholar
  3. 3.
    Aapro M, Rugo H, Rossi G et al (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117–121CrossRefPubMedGoogle Scholar
  5. 5.
    Bymaster FP, Calligaro DO, Falcone JF et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96CrossRefPubMedGoogle Scholar
  6. 6.
    Coates A, Abraham S, Kaye SB et al (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503CrossRefPubMedGoogle Scholar
  8. 8.
    Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777–794CrossRefPubMedGoogle Scholar
  9. 9.
    Ettinger DS, Berger MJ, Aston J et al (2017) NCCN guidelines; Antiemesis, version 2.2017. http://nccn.org. Zugegriffen: 9. Dez. 2017Google Scholar
  10. 10.
    Geling O, Eichler HG (2005) Should 5‑hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294CrossRefPubMedGoogle Scholar
  11. 11.
    Gralla RJ, Bosnjak SM, Hontsa A et al (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Gralla RJ, Itri LM, Pisko SE et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909CrossRefPubMedGoogle Scholar
  13. 13.
    Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994CrossRefPubMedGoogle Scholar
  14. 14.
    Grunberg S, Chua D, Maru A et al (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol 29:1495–1501CrossRefPubMedGoogle Scholar
  15. 15.
    Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? J Support Oncol 2:1–12PubMedGoogle Scholar
  16. 16.
    Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268CrossRefPubMedGoogle Scholar
  17. 17.
    Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13:80–84CrossRefPubMedGoogle Scholar
  18. 18.
    Hesketh PJ, Aapro M, Street JC et al (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171–1177CrossRefPubMedGoogle Scholar
  19. 19.
    Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119CrossRefPubMedGoogle Scholar
  20. 20.
    Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261CrossRefPubMedGoogle Scholar
  21. 21.
    Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103–109CrossRefPubMedGoogle Scholar
  22. 22.
    Jordan K, Gralla R, Jahn F et al (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202CrossRefPubMedGoogle Scholar
  23. 23.
    Kamen C, Tejani MA, Chandwani K et al (2014) Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 722:172–179CrossRefPubMedGoogle Scholar
  24. 24.
    Licup N (2010) Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 27:432–434CrossRefPubMedGoogle Scholar
  25. 25.
    Navari RM (2014) Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol 722:180–186CrossRefPubMedGoogle Scholar
  26. 26.
    Navari RM (2015) Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther 9:155–161PubMedGoogle Scholar
  27. 27.
    Navari RM, Einhorn LH, Passik SD et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13:529–534CrossRefPubMedGoogle Scholar
  28. 28.
    Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195CrossRefPubMedGoogle Scholar
  29. 29.
    Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663CrossRefPubMedGoogle Scholar
  30. 30.
    Perwitasari DA, Gelderblom H, Atthobari J et al (2011) Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33:33–43CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMedGoogle Scholar
  32. 32.
    Raftopoulos H, Cooper W, O’Boyle E et al (2015) Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 23:723–732CrossRefPubMedGoogle Scholar
  33. 33.
    Rapoport B, Chua D, Poma A et al (2015) Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 23:3281–3288CrossRefPubMedGoogle Scholar
  34. 34.
    Rapoport BL, Chasen MR, Gridelli C et al (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079–1089CrossRefPubMedGoogle Scholar
  35. 35.
    Rapoport BL, Jordan K, Boice JA et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefPubMedGoogle Scholar
  36. 36.
    Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(v119):v133Google Scholar
  37. 37.
    Schwartzberg L, Barbour SY, Morrow GR et al (2014) Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer 22:469–477CrossRefPubMedGoogle Scholar
  38. 38.
    Shadle CR, Lee Y, Majumdar AK et al (2004) Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 44:215–223CrossRefPubMedGoogle Scholar
  39. 39.
    Spartinou A, Nyktari V, Papaioannou A (2017) Granisetron: a review of pharmacokinetics and clinical experience in chemotherapy induced—nausea and vomiting. Expert Opin Drug Metab Toxicol 13:1289–1297CrossRefPubMedGoogle Scholar
  40. 40.
    Tafelski S, Hauser W, Schafer M (2016) Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews. Schmerz 30:14–24CrossRefPubMedGoogle Scholar
  41. 41.
    Tageja N, Groninger H (2016) Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines. Postgrad Med J 92:34–40CrossRefPubMedGoogle Scholar
  42. 42.
    Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Urologische Klinik und Poliklinik, Klinikum rechts der IsarTechnische Universität MünchenMünchenDeutschland

Personalised recommendations

Cite article

Buy options